Novo Nordisk agrees to buy Chinese weight-loss pill for 2.5 billion euros

{
  "signal_id": "5ce7ddcc-c72d-c18a-b66b-df051a429fa6",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-09-29T11:58:06+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.elespanol.com/invertia/observatorios/sanidad/20260929/novo-nordisk-acuerda-compra-pildora-china-adelgazar-millones-euros/1003744401224_0.html",
    "title": "Novo Nordisk agrees to buy Chinese weight-loss pill for 2.5 billion euros - El Español",
    "excerpt": "Novo Nordisk logo at the company's headquarters in Germany. Europa Press. Novo Nordisk will acquire the rights to a Chinese weight-loss pill from Jiangsu Hengrui Pharmaceuticals for up to 2.5 billion euros. The agreement strengthens Novo Nordisk's position against its main rival Eli Lilly, in a rapidly growing global market for obesity therapies.Hengrui will receive an upfront payment of 264 million euros and could obtain up to an additional 2.026 billion for development and commercialization milestones. The experimental pill HRS-1596 is approved in China for clinical trials for weight management and type 2 diabetes.Novo Nordisk intensifies its presence in the obesity market. The Danish pharmaceutical company will pay up to 2.6 billion dollars (2.467 billion euros at the current exchange rate) to Jiangsu Hengrui Pharmaceuticals to obtain the rights to an experimental weight-loss pill, expanding its product portfolio through a second GLP-1 treatment agreement with its Chinese partner.This agreement helps Novo strengthen its competitive position against its main rival Eli Lilly, amidst a wave of patent losses set to expire in the next decade. Its shares have plummeted more than 70% from their historical highs due to competition from Lilly. Novo reached its historical high in June 2024. At that time, the share price reached 1,004 Danish kroner (about 134.29 euros) compared to the...",
    "product": "HRS-1596",
    "summary": "Novo Nordisk has agreed to acquire the rights to an experimental weight-loss pill, HRS-1596, from Jiangsu Hengrui Pharmaceuticals for up to 2.5 billion euros, including an upfront payment of 264 million euros.",
    "planning": true,
    "image_url": "https://s3.elespanol.com/k/imgp/cms/elespanol/11035337.jpg?p=f:jpeg/c:3808:2142:nowe:0:354/w:1706/h:960&h=QMY_Kx6s",
    "confidence": 0.9,
    "product_data": {
      "name": "HRS-1596",
      "full_text": "The experimental pill HRS-1596",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-29T11:58:06Z",
    "article_sentence": "Novo Nordisk will acquire the rights to a Chinese weight-loss pill from Jiangsu Hengrui Pharmaceuticals for up to 2.5 billion euros.",
    "related_company_name": "Jiangsu Hengrui Pharmaceuticals",
    "related_company_domain": "hrs.com.cn"
  }
}

curl https://signals.autobound.ai/v1/signals/5ce7ddcc-c72d-c18a-b66b-df051a429fa6 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novonordisk.com","limit":20}'